Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 55% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 17.0% — good return on equity
HAEMONETICS CORPORATION (HAE) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $2.8 billion . Key value metrics: P/E ratio 17.9, P/B ratio 3.03, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
HAEMONETICS CORPORATION — Fundamental Analysis Summary
HAEMONETICS CORPORATION (HAE) is currently trading 55% above its Graham Number of $38.36, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 17.9x.
On financial health, HAE shows a moderate Piotroski F-Score of 6/9, and solid return on equity of 17.0% (sector average: -19.8%), and elevated leverage with a debt-to-equity ratio of 1.34.
StockPik's composite Value Score for HAE is 82/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
HAE reports a solid gross margin of 58.6% (sector average: 33.5%) and a solid operating margin of 17.9%.
HAE shows revenue growing at 4% year-over-year, with earnings growing at 43%.